Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer

Cancer

Volumn 116, Issue 12, 2010, Pages 2941-2953

  Yeh, Jennifer M ^a   Hur, Chin ^b   Kuntz, Karen M ^c   Ezzati, Majid ^a   Goldie, Sue J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cost effectiveness; Gastric cancer; Outcomes research; Secondary prevention; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; ENDOSCOPIC MUCOSAL RESECTION; GASTROINTESTINAL DYSPLASIA; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HUMAN; INTESTINE ATROPHY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STOMACH CANCER; STOMACH LESION; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; ENDOSCOPY; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 77953966862     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25030     Document Type: Article

References (62)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, Version 2.0. Lyon, France: IARC Press; 2004.
2. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007;12:1-15. (Pubitemid 46105914)
3. Richter JE. Gastrooesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2007;21:609-631.
4. National Cancer Institute. Report of the Stomach/Esophageal Cancer Progress Review Group. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2002.
5. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103:788-797.
6. Genta RM, Rugge M. Review article: pre-neoplastic states of the gastric mucosa - a practical approach for the perplexed clinician. Aliment Pharmacol Ther. 2001;15(suppl 1):43-50.
7. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63:570-580.
8. Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology. 1994;107: 1288-1296.
9. Weinstein WM, Goldstein NS. Gastric dysplasia and its management. Gastroenterology. 1994;107:1543-1545.
10. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut. 1991;32:1110-1113.
11. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002;50:378-381. (Pubitemid 34161055)
12. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology. 2003;125:586-590. (Pubitemid 36929439)
13. West AB, Fischer R, Kapadia C, Genta RM, Wang TC, Lauwers GY. What and whom to treat with metaplasia. J Clin Gastroenterol. 2003;36(suppl 1):S61-S62.
14. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Moreira-Dias L. We would welcome guidelines for surveillance of patients with gastric atrophic chronic and intestinal metaplasia! Helicobacter. 2008;13:75-76.
15. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006;24(suppl 3):S155-S163.
16. Yeh JM, Kuntz KM, Ezzati M, Hur C, Kong CY, Goldie SJ. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev. 2008;17:1179-1187.
17. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
18. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345: 1525-1528.
19. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50:4737-4740. (Pubitemid 20230422)
20. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer. 1999;83:615-619.
21. Craanen ME, Dekker W, Ferwerda J, Blok P, Tytgat GN. Early gastric cancer: a clinicopathologic study. J Clin Gastroenterol. 1991;13:274-283.
22. Fennerty MB, Emerson JC, Sampliner RE, McGee DL, Hixson LJ, Garewal HS. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. Cancer Epidemiol Biomarkers Prev. 1992;1:293-296.
23. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004 Incidence and Mortality [web-based report]. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007.
24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston, 1994. Am J Surg Pathol. 1996;20: 1161-1181.
25. Hosokawa O, Tsuda S, Kidani E, et al. Diagnosis of gastric cancer up to 3 years after negative upper gastrointestinal endoscopy. Endoscopy. 1998;30:669-674. (Pubitemid 28528739)
26. Guarner J, Herrera-Goepfert R, Mohar A, et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol. 2003;34:28-31. (Pubitemid 36160018)
27. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
28. Wang YP, Bennett C, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2006;(1):CD004276.
29. Schauer PR, Schwesinger WH, Page CP, Stewart RM, Levine BA, Sirinek KR. Complications of surgical endoscopy. A decade of experience from a surgical residency training program. Surg Endosc. 1997;11:8-11.
30. Silvis SE, Nebel O, Rogers G, Sugawa C, Mandelstam P. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA. 1976; 235:928-930.
31. Bearzi I, Brancorsini D, Santinelli A, Rezai B, Mannello B, Ranaldi R. Gastric dysplasia: a ten-year follow-up study. Pathol Res Pract. 1994;190:61-68. (Pubitemid 24106587)
32. Koch HK, Oehlert M, Oehlert W. An evaluation of gastric dysplasia in the years 1986 and 1987. Pathol Res Pract. 1990;186:80-84.
33. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945-952. (Pubitemid 351451990)
34. Takekoshi T, Baba Y, Ota H, et al. Endoscopic resection of early gastric carcinoma: results of a retrospective analysis of 308 cases. Endoscopy. 1994;26:352-358.
35. Kojima T, Parra-Blanco A, Takahashi H, Fujita R. Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. Gastrointest Endosc. 1998;48:550-554; discussion 554-555.
36. Nagano H, Ohyama S, Fukunaga T, et al. Indications for gastrectomy after incomplete EMR for early gastric cancer. Gastric Cancer. 2005;8:149-154.
37. Finlayson EV, Birkmeyer JD. Operative mortality with elective surgery in older adults. Eff Clin Pract. 2001;4:172-177.
38. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48: 225-229. (Pubitemid 32141848)
39. Ida K, Nakazawa S, Yoshino J, et al. Multicentre collaborative prospective study of endoscopic treatment of early gastric cancer. Dig Endosc. 2004;16:295-302. (Pubitemid 39421394)
40. Tanabe S, Koizumi W, Mitomi H, et al. Clinical outcome of endoscopic aspiration mucosectomy for early stage gastric cancer. Gastrointest Endosc. 2002;56:708-713.
41. Makuuchi H, Kise Y, Shimada H, Chino O, Tanaka H. Endoscopic mucosal resection for early gastric cancer. Semin Surg Oncol. 1999;17:108-116.
42. Lauwers GY, Ban S, Mino M, et al. Endoscopic mucosal resection for gastric epithelial neoplasms: a study of 39 cases with emphasis on the evaluation of specimens and recommendations for optimal pathologic analysis. Mod Pathol. 2004;17:2-8.
43. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer. 2006;118:2315-2321.
44. Miyamoto A, Kuriyama S, Nishino Y, et al. Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. Prev Med. 2007;44:12-19. (Pubitemid 46073076)
45. U.S. Department of Health and Human Services, Center for Medicare and Medicaid Services. Fee Schedule. Washington, DC: U.S. Department of Health and Human Services, Center for Medicare and Medicaid Services; 2007.
46. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100:630-641.
47. Bureau of Labor Statistics, U.S. Department of Labor. Occupational Employment and Wages. Washington, DC: U.S. Government Printing Office; 2007.
48. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007; 99:14-23.
49. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26: 391-400. (Pubitemid 44050843)
50. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778-792. (Pubitemid 128454315)
51. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308. (Pubitemid 34791317)
52. Lauwers GY, Srivastava A. Gastric preneoplastic lesions and epithelial dysplasia. Gastroenterol Clin North Am. 2007; 36:813-829, vi.
53. Camilleri JP, Potet F, Amat C, Molas G. Gastric muscosal dysplasia: preliminary results of a prospective study of patients followed for periods of up to 6 years. In: Ming SC, ed. Precursors of Gastric Cancer. New York: Praeger; 1984.
54. Farinati F, Rugge M, Di Mario F, Valiante F, Baffa R. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D. - Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy. 1993;25:261-264.
55. Sharma P, Falk GW, Sampliner R, Jon Spechler S, Wang K. Management of nondysplastic Barrett's esophagus: where are we now? Am J Gastroenterol. 2009;104:805-808.
56. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000;19:92-109.
57. Jass JR. Discrepancies between East and West. Cancer. 2000; 88:969-970.
58. Naylor GM, Gotoda T, Dixon M, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55: 1545-1552. (Pubitemid 44629199)
59. Everett SM, Axon AT. Early gastric cancer: disease or pseudo-disease? Lancet. 1998;351:1350-1352.
60. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372:392-397.
61. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of 3 treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974-983.
62. de Vries AC, Meijer GA, Looman CW, et al. Epidemiological trends of premalignant gastric lesions: a long-term nationwide study in the Netherlands. Gut. 2007;56:1665-1670.